Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens for breast cancer.

× No keyword cloud information.

5 in total

1. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

Authors: M S Aapro; J Bohlius; D A Cameron; Lissandra Dal Lago; J Peter Donnelly; N Kearney; G H Lyman; R Pettengell; V C Tjan-Heijnen; J Walewski; Damien C Weber; C Zielinski
Journal: Eur J Cancer Date: 2010-11-20 Impact factor: 9.162

2. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.

Authors: Vicente Valero; John Forbes; Mark D Pegram; Tadeusz Pienkowski; Wolfgang Eiermann; Gunter von Minckwitz; Henri Roche; Miguel Martin; John Crown; John R Mackey; Pierre Fumoleau; Janusz Rolski; Zrinka Mrsic-Krmpotic; Agnieszka Jagiello-Gruszfeld; Alessandro Riva; Marc Buyse; Henry Taupin; Guido Sauter; Michael F Press; Dennis J Slamon
Journal: J Clin Oncol Date: 2010-11-29 Impact factor: 44.544

3. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

Authors: Stephen E Jones; Michael A Savin; Frankie Ann Holmes; Joyce A O'Shaughnessy; Joanne L Blum; Svetislava Vukelja; Kristi J McIntyre; John E Pippen; James H Bordelon; Robert Kirby; John Sandbach; William J Hyman; Pankaj Khandelwal; Angel G Negron; Donald A Richards; Stephen P Anthony; Robert G Mennel; Kristi A Boehm; Walter G Meyer; Lina Asmar
Journal: J Clin Oncol Date: 2006-12-01 Impact factor: 44.544

4. Adjuvant trastuzumab in HER2-positive breast cancer.

Authors: Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown
Journal: N Engl J Med Date: 2011-10-06 Impact factor: 91.245

5. Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens.

Authors: Derek Weycker; Xiaoyan Li; John Edelsberg; Rich Barron; Alex Kartashov; Hairong Xu; Gary H Lyman
Journal: Support Care Cancer Date: 2014-08-01 Impact factor: 3.603

5 in total